Editorials

1107 Shades of Grey: The Conundrum of Implantable Defibrillators in Individuals with Advanced CKD
Aisha Khattak and David M. Charytan
See related article on page 1119.

1110 Treating Elderly Patients with ANCA-Associated Vasculitis
J. Ashley Jefferson
See related article on page 1128.

1114 Nonblood/Urine Biomarker of Progression of Kidney Disease in Diabetes Mellitus
Ramin Tolouian and Aaron I. Vinik
See related article on page 1136.

1117 ESRD Outcomes and GN Subtypes
Eric W. Young
See related article on page 1170.

Original Articles

Chronic Kidney Disease

1119 Implantable Cardioverter-Defibrillators in Patients with CKD: A Propensity-Matched Mortality Analysis
See related editorial on page 1107.

Clinical Nephrology

1128 Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis
See related editorial on page 1110.

Diabetes and the Kidney

1136 Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Nonmacroalbuminuric Type 1 Diabetes
Steven Orlov, David Z.I. Cherney, Rodica Pop-Busui, Leif E. Lovblom, Linda H. Ficociello, Adam M. Smiles, James H. Warram, Andrzej S. Krolewski, and Bruce A. Perkins
See related editorial on page 1114.

Epidemiology and Outcomes

1145 Light-Intensity Physical Activities and Mortality in the United States General Population and CKD Subpopulation
Srinivasan Beddhu, Guo Wei, Robin L. Marcus, Michel Chonchol, and Tom Greene

1154 Rate of Change in Renal Function and Mortality in Elderly Treated Hypertensive Patients
Enayet K. Chowdhury, Robyn G. Langham, Zanfina Ademi, Alice Owen, Henry Krum, Lindon M.H. Wing, Mark R. Nelson, and Christopher M. Reid, on behalf of the Second Australian National Blood Pressure Study Management Committee
1162 Serum 25-Hydroxyvitamin D Level and Kidney Function Decline in a Swiss General Adult Population
Idris Guessous, William McClellan, David Kleinbaum, Viola Vaccarino, Henry Hugues, Olivier Boulou, Pedro Marques-Vidal, Fred Paccaud, Jean-Marc Theler, Jean-Michel Gaspoz, Michel Burnier, Gérard Waeber, Peter Vollenweider, and Murielle Bochud

1170 Patient Characteristics and Outcomes by GN Subtype in ESRD
Michelle M. O’Shaughnessy, Maria E. Montez-Rath, Richard A. Lafayette, and Wolfgang C. Winkelmayer
See related editorial on page 1117.

ESRD and Chronic Dialysis

1179 Changes in Pulse Pressure during Hemodialysis Treatment and Survival in Maintenance Dialysis Patients
Paungpaga Lertdumrongluk, Elani Streja, Connie M. Rhee, John J. Sim, Daniel Gillen, Csaba P. Kovesdy, and Kamyar Kalantar-Zadeh

1192 Body Composition and Survival in Dialysis Patients: Results from an International Cohort Study
Daniele Marcelli, Len A. Usyvat, Peter Kotanko, Inga Bayh, Bernard Canaud, Michael Etter, Emanuele Gatti, Aileen Grassmann, Yuedong Wang, Cristina Marelli, Laura Scatizzi, Andrea Stopper, Frank M. van der Sande, and Jeroen Kooman, on behalf of the MONitoring Dialysis Outcomes (MONDO) Consortium

1201 Patient and Health Care Professional Decision-Making to Commence and Withdraw from Renal Dialysis: A Systematic Review of Qualitative Research
Jamilla A. Hussain, Kate Flemming, Fliss E.M. Murtagh, and Miriam J. Johnson

Ethics

1217 Focus Group Study of Public Opinion About Paying Living Kidney Donors in Australia
Allison Tong, Angelique F. Ralph, Jeremy R. Chapman, Germaine Wong, John S. Gill, Michelle A. Josephson, and Jonathan C. Craig

Hypertension

1227 Effect of Dietary Sodium Restriction on Human Urinary Metabolomic Profiles
Kristen L. Jablonski, Jelena Klawitter, Michel Chonchol, Candace J. Bassett, Matthew L. Racine, and Douglas R. Seals

Nephrolithiasis

1235 Clinical and Genetic Analysis of Patients with Cystinuria in the United Kingdom
Hannah L. Rhodes, Laura Yarram-Smith, Sarah J. Rice, Ayla Tabakser, Noel Edwards, Alice Hartley, Mark N. Woodward, Sarah L. Smithson, Charles Tomson, Gavin I. Welsh, Margaret Williams, David T. Thwaites, John A. Sayer, and Richard J.M. Coward

Renal Transplantation

1246 The Association between Marine n-3 Polyunsaturated Fatty Acid Levels and Survival after Renal Transplantation
Ivar A. Eide, Trond Jenssen, Anders Hartmann, Lien M. Diep, Dag O. Dahle, Anna V. Reisæter, Kristian S. Bjerve, Jeppe H. Christensen, Erik B. Schmidt, and My Svensson

Renal Physiology

1257 Renal Control of Calcium, Phosphate, and Magnesium Homeostasis
Judith Blaine, Michel Chonchol, and Moshe Levi

Renal Immunology

1273 A New CJASN Series: Renal Immunology for the Clinician
Fadi G. Lakkis and Paul M. Palevsky

1274 A Brief Journey through the Immune System
Karim M. Yatim and Fadi G. Lakkis
Renal hemosiderosis occurs as a complication of intravascular hemolysis. Hemolytic anemias, mismatched blood transfusions, paroxysmal nocturnal hemoglobinuria and mechanical hemolysis from prosthetic cardiac valves are the common causes. Intravascular haemolysis releases hemoglobin (Hb) into plasma, where it binds to plasma haptoglobin (Hp), forming Hb–Hp complex. This complex is not filtered by the glomerulus and is degraded by the liver. In chronic hemolytic states, plasma haptoglobin is consumed. Unbound (free) Hb accumulates in plasma and is filtered by the glomerulus. It is reabsorbed by the proximal tubule cells, resulting in the accumulation of ferric ions (hemosiderin) and subsequent cell injury.

Renal hemosiderosis seldom causes renal dysfunction and is usually an incidental radiologic or autopsy finding. In cases with clinical involvement, it causes reversible acute dysfunction to chronic irreversible damage. Treatment is usually directed to the underlying disease. Iron chelation therapy may be helpful.

(Image and text provided by Anila Kurien, Center for Renal and Urological Pathology Pvt Ltd Chennai, Tamil Nadu, India, and Edwin Fernando, Government Stanley Medical College, Nephrology Chennai, Tamil Nadu, India)